A Trial for the Treatment of Cardiac AL-Amyloidosis With the Green Tea Compound Epigallocatechin-3-gallate (TAME-AL)
Status:
Completed
Trial end date:
2017-10-11
Target enrollment:
Participant gender:
Summary
Efficacy and safety of epigallocatechin-3-gallate (EGCG) in patients with cardiac amyloid
light-chain (AL) amyloidosis. Evaluation of clinical efficacy of EGCG intake using a pretest
posttest comparison of left ventricular amyloid mass (g/m2) measured by cardiac MRI.